IPO - IMMUNIC, INC.

Form Type: 8-K

Filing Date: 2025-05-28

Corporate Action: Ipo

Type: New

Accession Number: 000119380525000730

Filing Summary: On May 28, 2025, Immunic, Inc. announced the commencement of an underwritten public offering of pre-funded warrants to purchase shares of its common stock, series A warrants, and series B warrants. These securities are linked to an effective registration statement previously filed on November 22, 2023, and declared effective by the SEC on May 31, 2024. The Company has issued a preliminary prospectus supplement for this offering on the same date. Additionally, the Company published an updated corporate presentation detailing extended data from its phase 2 CALLIPER trial of vidofludimus calcium, an investigational drug for chronic inflammatory and autoimmune diseases. The updated corporate presentation was made available on the Company’s website on the same day, May 28, 2025.